7 terminated, 6 completed, 1 recruiting, 1 withdrawn. 11 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 5, Terminated 5, Recruiting 1 |
| Phase 2 | 5 | Terminated 3, Completed 1, Withdrawn 1 |
Follow Adaptimmune: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma ADP-TILIL7, Cyclophosphamide, Fludarabine Phosphate - Melanoma Stage III, Melanoma Stage IV | Phase 1 | Recruiting | Inge Marie Svane | 10 | 2025-04-01 | 2025-08-24 |
| ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2) Autologous genetically modified ADP-A2M4CD8 cells - Esophageal Cancer, Esophagogastric Junction Cancer | Phase 2 | Terminated | Adaptimmune | 3 | 2021-09-15 | 2024-09-04 |
| Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer GSK3901961, Cyclophosphamide, Fludarabine - Neoplasms | Phase 1 | Terminated | Adaptimmune | 7 | 2021-03-09 | 2024-11-13 |
| Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma GSK3845097, Cyclophosphamide, Fludarabine - Neoplasms | Phase 1 | Terminated | Adaptimmune | 5 | 2020-12-21 | 2024-11-13 |
| Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors GSK3901961, GSK3845097, GSK4427296 - Neoplasms | Phase 1 | Terminated | Adaptimmune | 12 | 2020-12-21 | 2024-11-26 |
| SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer ADP-A2M4 in combination with pembrolizumab. - Head and Neck Cancer | Phase 2 | Withdrawn | Adaptimmune | 2020-07-02 | 2021-11-16 | |
| Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors Genetically engineered T Cell Receptors - Solid and Hematological Malignancies | Terminated | Adaptimmune | 2 | 2018-02-28 | 2021-01-07 | |
| AFPᶜ³³²T in Advanced HCC Autologous genetically modified AFPᶜ³³²T cells - Hepatocellular Cancer, AFP Expressing Tumors | Phase 1 | Completed | Adaptimmune | 39 | 2017-05-08 | 2026-06-17 |
| MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells - Urothelial Carcinoma, Head and Neck Cancer | Phase 1 | Completed | Adaptimmune | 10 | 2016-10-01 | 2026-02-04 |
| Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination Solid and Hematological Malignancies | Completed | Adaptimmune | 9122 | 2015-12-01 | 2025-03-04 | |
| MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T - Non-Small Cell Lung Cancer, Carcinoma | Phase 1 | Completed | Adaptimmune | 28 | 2015-11-01 | 2025-12-09 |
| CT Antigen TCR-Engineered T Cells for Myeloma Treatment with NY-ESO-1c259-modified T cells - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Adaptimmune | 6 | 2013-10-15 | 2019-01-10 |
| CT Antigen TCR-redirected T Cells for Ovarian Cancer. NYESO-1c259 T cells - Ovarian Cancer | Phase 1 / Phase 2 | Completed | Adaptimmune | 9 | 2013-07-09 | 2019-06-27 |
| Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma Autologous genetically modified T cells, NY-ESO-1ᶜ²⁵⁹T - Melanoma | Phase 1 / Phase 2 | Terminated | Adaptimmune | 4 | 2011-06-01 | 2019-01-10 |
| Redirected High Affinity Gag-Specific Autologous T Cells for HIV Gene Therapy WT-gag-TCR modified T cells, α/6-gag-TCR modified T cells, STI or Drug Holiday - HIV Infections | Phase 1 | Completed | University of Pennsylvania | 2 | 2009-11-01 | 2019-10-10 |
Neoplasm Metastasis (8) · Neoplasms (5) · Liposarcoma, Myxoid (3) · Melanoma (3) · Carcinoma, Non-Small-Cell Lung (2) · Head and Neck Neoplasms (2) · Hematologic Neoplasms (2) · Carcinoma (1) · Carcinoma, Transitional Cell (1) · Esophageal Neoplasms (1) · HIV Infections (1) · Liver Neoplasms (1) · Multiple Myeloma (1) · Ovarian Neoplasms (1)
Cyclophosphamide (4) · fludarabine (3) · Therapeutics (1) · Treatment Interruption (1) · aldesleukin (1) · fludarabine phosphate (1) · pembrolizumab (1)
United States (14) · Canada (8) · Spain (5) · Australia (3) · Germany (3) · Netherlands (3) · Sweden (3) · United Kingdom (3) · Denmark (1) · France (1)
Adaptimmune Patient Enquiries (3) · Ben Creelan, MD, MS (1) · Cecilie D Vestergaard, M.D. (1) · David Hong, MD (1) · Edward Stadtmauer, MD (1) · Gerald P Linette, MD, PhD (1) · Harriet Kluger, MD (1) · Inge Marie Svane, Prof., M.D. (1) · Kunle Odunsi, MD, PhD (1) · Marcus Butler, MD (1) · Richard S Finn, MD (1)
PMID 35086946, PMID 35372008, PMID 40812667
2019 (2), 2017 (1)